- ProPhase Labs Inc PRPH has acquired privately-held Nebula Genomics for approximately $14.6 million in a combination of stock and cash.
- Prophase will integrate Nebula's whole genome sequencing services with its clinical diagnostic testing services.
- ThinkEquity, a division of Fordham Financial Management Inc, acted as advisor to ProPhase.
- Nebula Genomics currently provides consumers access to affordable and secure whole-genome sequencing via its online portal.
- Price Action: PRPH shares are down 9.92% at $6.91 during the market session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
